Synthesis, Characterization, DNA Binding, Docking, and Anticancer Studies of Novel Bis-1,2,3-triazoles Phthalonitrile

被引:22
作者
Yahya Alraqa, Shaya [1 ]
Alsayed Soliman, Moataz [1 ]
Aljuhani, Ateyatallah [1 ]
Rezki, Nadjet [1 ]
Reda Aouad, Mohamed [1 ]
Ali, Imran [1 ,2 ]
机构
[1] Taibah Univ, Fac Sci, Dept Chem, Al Madinah Al Munawarah 30002, Saudi Arabia
[2] Jamia Millia Islamia, Dept Chem, New Delhi 110025, India
来源
CHEMISTRYSELECT | 2020年 / 5卷 / 36期
关键词
Antitumor agent; Bis-1; 2; 3-triazoles; Click chemistry; Cancer; DNA binding; Docking; Phtalonitrile; CLICK CHEMISTRY; GLUTAMIC-ACID; COMPLEXES; 1,2,3-TRIAZOLES; COPPER(II); DESIGN; DRUG; DERIVATIVES; THALIDOMIDE; NICKEL(II);
D O I
10.1002/slct.202003296
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Due to a great demand of new anticancer agents, novel series of phtalonitrile-bis(1,2,3-triazoles) appended with different functionalities were synthesized and characterized by FTIR,H-1 NMR,C-13 NMR and mass spectroscopy techniques. These were also screened for DNA binding, docking and anticancer activities. The DNA binding constants were in the range of 1.33x10(5)to 12.60x10(5) M-1; indicating strong binding affinity. The maximum anticancer activity was 79 % in A549 and H1299 lung cancer cell lines. The docking study suggested good interactions of the reported molecules with DNA through hydrogen bonding and hydrophobic interactions. All these results confirmed that the reported molecules have good anticancer activities. Therefore, these 1,2,3-triazole scaffolds may be promising molecules as potential anticancer candidates in the future.
引用
收藏
页码:11347 / 11353
页数:7
相关论文
共 40 条
  • [1] Click Chemistry: 1,2,3-Triazoles as Pharmacophores
    Agalave, Sandip G.
    Maujan, Suleman R.
    Pore, Vandana S.
    [J]. CHEMISTRY-AN ASIAN JOURNAL, 2011, 6 (10) : 2696 - 2718
  • [2] Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents
    Al-blewi, Fawzia Faleh
    Almehmadi, Meshal A.
    Aouad, Mohamed Reda
    Bardaweel, Sanaa K.
    Sahu, Pramod K.
    Messali, Mouslim
    Rezki, Nadjet
    El Ashry, El Sayed H.
    [J]. CHEMISTRY CENTRAL JOURNAL, 2018, 12
  • [3] Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
    Ali, I.
    [J]. CURRENT CANCER DRUG TARGETS, 2011, 11 (02) : 131 - 134
  • [4] Enantioselective toxicity and carcinogenesis
    Ali, Imran
    Aboul-Enein, Hassan Y.
    Ghanem, Ashraf
    [J]. CURRENT PHARMACEUTICAL ANALYSIS, 2005, 1 (01) : 109 - 125
  • [5] Imidazoles as potential anticancer agents
    Ali, Imran
    Lone, Mohammad Nadeem
    Aboul-Enein, Haasan Y.
    [J]. MEDCHEMCOMM, 2017, 8 (09) : 1742 - 1773
  • [6] Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
    Ali, Imran
    Lone, Mohammad Nadeem
    Al-Othman, Zeid A.
    Al-Warthan, Abdulrahman
    Sanagi, Mohd Marsin
    [J]. CURRENT DRUG TARGETS, 2015, 16 (07) : 711 - 734
  • [7] Anticancer metallodrugs of glutamic acid sulphonamides: in silico, DNA binding, hemolysis and anticancer studies
    Ali, Imran
    Wani, Waseem A.
    Saleem, Kishwar
    Hsieh, Ming-Fa
    [J]. RSC ADVANCES, 2014, 4 (56): : 29629 - 29641
  • [8] Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
    Ali, Imran
    Wani, Waseem A.
    Saleem, Kishwar
    Haque, Ashanul
    [J]. CURRENT DRUG THERAPY, 2012, 7 (01) : 13 - 23
  • [9] Design and synthesis of thalidomide based dithiocarbamate Cu(II), Ni(II) and Ru(III) complexes as anticancer agents
    Ali, Imran
    Wani, Waseem A.
    Saleem, Kishwar
    Hseih, Ming-Fa
    [J]. POLYHEDRON, 2013, 56 : 134 - 143
  • [10] Ali I, 2013, FUTURE MED CHEM, V5, P961, DOI [10.4155/FMC.13.62, 10.4155/fmc.13.62]